Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

NCT03556358 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

809

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Neoplasms
HER2-positive Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer

Interventions

BIOLOGICAL: TX05 (trastuzumab)
BIOLOGICAL: Herceptin®
DRUG: Paclitaxel
DRUG: Epirubicin
DRUG: Cyclophosphamide

Sponsor

Tanvex BioPharma USA, Inc.